التفاصيل البيبلوغرافية
| العنوان: |
Data from A Novel Small-Molecule Inhibitor of Protein Kinase D Blocks Pancreatic Cancer Growth In vitro and In vivo |
| المؤلفون: |
Sushovan Guha, Christopher R. Ireson, Enrique Rozengurt, Bharat B. Aggarwal, Sunil Krishnan, Juri Gelovani, James Sinnett-Smith, Yoichi Matsuo, Parmeswaran Diagaradjane, Dipen Maru, Muddasar Farooq, Alexandra Boakes, Caroline Foxton, Azadeh Bagherzadeh, Mark Charles, Tony Raynham, Rachel Sutherland, Stephen Jamieson, Lloyd Kelland, Bokyung Sung, Amit Deorukhkar, Zhimin Tong, Nobuo Ochi, Ajaikumar B. Kunnumakkara, Kuzhuvelil B. Harikumar |
| بيانات النشر: |
American Association for Cancer Research (AACR), 2023. |
| سنة النشر: |
2023 |
| الوصف: |
Protein kinase D (PKD) family members are increasingly implicated in multiple normal and abnormal biological functions, including signaling pathways that promote mitogenesis in pancreatic cancer. However, nothing is known about the effects of targeting PKD in pancreatic cancer. Our PKD inhibitor discovery program identified CRT0066101 as a specific inhibitor of all PKD isoforms. The aim of our study was to determine the effects of CRT0066101 in pancreatic cancer. Initially, we showed that autophosphorylated PKD1 and PKD2 (activated PKD1/2) are significantly upregulated in pancreatic cancer and that PKD1/2 are expressed in multiple pancreatic cancer cell lines. Using Panc-1 as a model system, we showed that CRT0066101 reduced bromodeoxyuridine incorporation; increased apoptosis; blocked neurotensin-induced PKD1/2 activation; reduced neurotensin-induced, PKD-mediated Hsp27 phosphorylation; attenuated PKD1-mediated NF-κB activation; and abrogated the expression of NF-κB-dependent proliferative and prosurvival proteins. We showed that CRT0066101 given orally (80 mg/kg/d) for 24 days significantly abrogated pancreatic cancer growth in Panc-1 subcutaneous xenograft model. Activated PKD1/2 expression in the treated tumor explants was significantly inhibited with peak tumor concentration (12 μmol/L) of CRT0066101 achieved within 2 hours after oral administration. Further, we showed that CRT0066101 given orally (80 mg/kg/d) for 21 days in Panc-1 orthotopic model potently blocked tumor growth in vivo. CRT0066101 significantly reduced Ki-67–positive proliferation index (P < 0.01), increased terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling–positive apoptotic cells (P < 0.05), and abrogated the expression of NF-κB–dependent proteins including cyclin D1, survivin, and cIAP-1. Our results show for the first time that a PKD-specific small-molecule inhibitor CRT0066101 blocks pancreatic cancer growth in vivo and show that PKD is a novel therapeutic target in pancreatic cancer. Mol Cancer Ther; 9(5); 1136–46. ©2010 AACR. |
| URL الوصول: |
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ab32f00e1cc289882edd000632bf0373
https://doi.org/10.1158/1535-7163.c.6531675.v1 |
| حقوق: |
OPEN |
| رقم الأكسشن: |
edsair.doi.dedup.....ab32f00e1cc289882edd000632bf0373 |
| قاعدة البيانات: |
OpenAIRE |
